Share on StockTwits

Endocyte (NASDAQ:ECYT) has received an average recommendation of “Buy” from the eleven ratings firms that are covering the company, reports. Three investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $23.49.

A number of research firms have recently commented on ECYT. Analysts at Brean Capital initiated coverage on shares of Endocyte in a research note on Tuesday, July 8th. They set a “buy” rating and a $22.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating in a research note on Monday, July 7th. They now have a $7.90 price target on the stock. Finally, analysts at Chardan Capital cut their price target on shares of Endocyte from $26.00 to $15.00 in a research note on Wednesday, June 18th. They now have a “buy” rating on the stock.

Shares of Endocyte (NASDAQ:ECYT) opened at 6.40 on Thursday. Endocyte has a 52-week low of $6.01 and a 52-week high of $33.70. The stock’s 50-day moving average is $6.57 and its 200-day moving average is $12.39. The company’s market cap is $265.6 million.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Friday, May 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The company had revenue of $17.30 million for the quarter, compared to the consensus estimate of $15.07 million. Analysts expect that Endocyte will post $-0.18 EPS for the current fiscal year.

Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.